130 related articles for article (PubMed ID: 26628427)
1. A Sensitivity Analysis to Assess Bias Due to Selecting Subjects Based on Treatment Received.
Ertefaie A; Small D; Flory J; Hennessy S
Epidemiology; 2016 Mar; 27(2):e5-7. PubMed ID: 26628427
[No Abstract] [Full Text] [Related]
2. PURLs: Need an add-on to metformin? Consider this.
Wyncott D; Lyon C; Mounsey A
J Fam Pract; 2017 Jan; 66(1):42-44. PubMed ID: 28188318
[TBL] [Abstract][Full Text] [Related]
3. Incorporating New Medications in Diabetes Care.
Comi RJ
Ann Intern Med; 2015 Nov; 163(9):719-20. PubMed ID: 26458033
[No Abstract] [Full Text] [Related]
4. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
5. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
6. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
7. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Christensen M; Knop FK
Nat Rev Endocrinol; 2012 Oct; 8(10):576-8. PubMed ID: 22926098
[No Abstract] [Full Text] [Related]
8. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
Nauck MA
Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
[No Abstract] [Full Text] [Related]
11. [Antidiabetic Drugs and the Kidney].
Candido R
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
[No Abstract] [Full Text] [Related]
12. Pharmacologic Agents Used to Treat Type 2 Diabetes.
Moran KJ; Burson R
Home Healthc Now; 2017; 35(7):394-395. PubMed ID: 28650371
[No Abstract] [Full Text] [Related]
13. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
Choby B
FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
[TBL] [Abstract][Full Text] [Related]
14. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
15. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Enders D; Kollhorst B; Engel S; Linder R; Verheyen F; Pigeot I
J Diabetes Complications; 2016; 30(7):1339-46. PubMed ID: 27245402
[TBL] [Abstract][Full Text] [Related]
16. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
17. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
18. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
19. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
20. (7) Approaches to glycemic treatment.
American Diabetes Association
Diabetes Care; 2015 Jan; 38 Suppl():S41-8. PubMed ID: 25537707
[No Abstract] [Full Text] [Related]
[Next] [New Search]